Patents by Inventor Daisuke Roland Saito
Daisuke Roland Saito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10377751Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: August 16, 2018Date of Patent: August 13, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
-
Publication number: 20190119267Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: August 16, 2018Publication date: April 25, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
-
Patent number: 9260414Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 12, 2014Date of Patent: February 16, 2016Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Patent number: 9227933Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: January 12, 2015Date of Patent: January 5, 2016Assignee: Theravance Biopharma R&D IP, LLCInventors: Eric Stangeland, Daisuke Roland Saito, Priscilla Van Dyke, Lori Jean Patterson
-
Patent number: 9206172Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 6, 2014Date of Patent: December 8, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
-
Patent number: 9199993Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: June 26, 2014Date of Patent: December 1, 2015Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
-
Publication number: 20150291579Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 6, 2014Publication date: October 15, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
-
Patent number: 9120746Abstract: The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.Type: GrantFiled: June 24, 2014Date of Patent: September 1, 2015Assignee: Theravance Biopharma R&D IP, LLCInventor: Daisuke Roland Saito
-
Publication number: 20150126577Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: January 12, 2015Publication date: May 7, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Eric Stangeland, Daisuke Roland Saito, Priscilla Van Dyke, Lori Jean Patterson
-
Patent number: 9000191Abstract: In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: November 26, 2013Date of Patent: April 7, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Eric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
-
Publication number: 20150080450Abstract: The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.Type: ApplicationFiled: June 24, 2014Publication date: March 19, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventor: Daisuke Roland Saito
-
Publication number: 20150071878Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 12, 2014Publication date: March 12, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Publication number: 20150051243Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: June 26, 2014Publication date: February 19, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
-
Patent number: 8933249Abstract: In one aspect, the invention relates to compounds of formula I: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: June 27, 2012Date of Patent: January 13, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Eric L. Stangeland, Priscilla Van Dyke, Timothy J. Church, Lori Jean Patterson, Daisuke Roland Saito
-
Patent number: 8921372Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 3, 2011Date of Patent: December 30, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa, Xiaojun Huang, Weijiang Zhang
-
Patent number: 8853255Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: April 25, 2013Date of Patent: October 7, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Eric L. Stangeland, Jane Schmidt, Daisuke Roland Saito, Adam D. Hughes, Lori Jean Patterson
-
Publication number: 20140243536Abstract: In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: November 26, 2013Publication date: August 28, 2014Applicant: THERAVANCE, INC.Inventors: Eric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
-
Patent number: 8802698Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: June 10, 2013Date of Patent: August 12, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Daisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
-
Patent number: 8791151Abstract: The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.Type: GrantFiled: December 19, 2012Date of Patent: July 29, 2014Assignee: Theravance Biopharma R&D IP, LLCInventor: Daisuke Roland Saito
-
Patent number: 8729119Abstract: In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: May 22, 2013Date of Patent: May 20, 2014Assignee: Theravance, Inc.Inventors: Eric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
